Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C
Authors
Keywords
-
Journal
PLoS One
Volume 7, Issue 4, Pages e35485
Publisher
Public Library of Science (PLoS)
Online
2012-04-20
DOI
10.1371/journal.pone.0035485
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer
- (2011) Carmen E. Gomez et al. CURRENT GENE THERAPY
- Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
- (2011) Paul A. Goepfert et al. JOURNAL OF INFECTIOUS DISEASES
- The HIV/AIDS Vaccine Candidate MVA-B Administered as a Single Immunogen in Humans Triggers Robust, Polyfunctional, and Selective Effector Memory T Cell Responses to HIV-1 Antigens
- (2011) C. E. Gomez et al. JOURNAL OF VIROLOGY
- Interplay between Modified Vaccinia Virus Ankara and Dendritic Cells: Phenotypic and Functional Maturation of Bystander Dendritic Cells
- (2011) M. F. Pascutti et al. JOURNAL OF VIROLOGY
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine
- (2011) Scott G. Hansen et al. NATURE
- Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors
- (2011) Esther D. Quakkelaar et al. PLoS One
- Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8+ T Cell Responses in HIV-1-Infected Individuals
- (2011) Núria Climent et al. PLoS One
- A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
- (2011) Juan García-Arriaza et al. PLoS One
- Improved NYVAC-Based Vaccine Vectors
- (2011) Karen V. Kibler et al. PLoS One
- Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation
- (2011) Y. Zhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
- (2011) B. J. Flynn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects☆☆☆
- (2011) Michael C. Keefer et al. VACCINE
- Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
- (2011) Felipe García et al. VACCINE
- Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
- (2010) M. Juliana McElrath et al. IMMUNITY
- Selective Induction of Host Genes by MVA-B, a Candidate Vaccine against HIV/AIDS
- (2010) S. Guerra et al. JOURNAL OF VIROLOGY
- Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine
- (2010) Sandhya Vasan et al. PLoS One
- Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens
- (2010) José Luis Nájera et al. PLoS One
- Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
- (2010) Juan García-Arriaza et al. PLoS One
- Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
- (2010) Jeffrey R. Currier et al. PLoS One
- Poxvirus vector-based HIV vaccines
- (2010) Giuseppe Pantaleo et al. Current Opinion in HIV and AIDS
- A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers
- (2009) Vadakkuppatu Devasenapathi Ramanathan et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge
- (2009) Scott G Hansen et al. NATURE MEDICINE
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
- (2009) Supachai Rerks-Ngarm et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens
- (2009) Carmen E. Gómez et al. VACCINE
- Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome
- (2009) Julie Delaloye et al. PLoS Pathogens
- An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
- (2008) Alexandre Harari et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus Ankara
- (2008) Eric Sandström et al. JOURNAL OF INFECTIOUS DISEASES
- Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates
- (2008) P. Mooij et al. JOURNAL OF VIROLOGY
- EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
- (2008) Sheena McCormack et al. VACCINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started